Elastrin Therapeutics
Antibody-targeted nanoparticle therapies for patients with vascular calcification and cardiovascular disease
Highlights
- Young companyFounded 2022
- New on EvolcAdded 2026-11-11
About Elastrin Therapeutics
Elastrin Therapeutics is developing antibody-guided nanoparticle therapies designed to target damaged elastin and reverse vascular calcification. Its platform uses a targeting antibody, liposomal nanoparticles and adaptable therapeutic payloads.
The company works with patients and physicians through therapeutic development and seeks co-development and regional partnerships with device and pharmaceutical companies. Its stated mission is to develop therapies that restore arterial elasticity and address vascular calcification.
The registered entity is based in Wantage, United Kingdom, and the company describes itself as operating in the US and UK. Its leadership includes a co-founder and chief scientific officer affiliated with Clemson University.
Product: A preclinical platform of antibody-targeted liposomal nanoparticles designed to deliver therapies to damaged elastin and reverse vascular calcification.
Jobs at Elastrin Therapeutics
Leadership
- Douglas Mulhall · Co-FounderSource: company website
- Shyam Parekh · Chief Executive OfficerSource: company website
- Narendra Vyavahare · Co-Founder & Chief Scientific OfficerSource: company website
- Valentin Busch · Co-founder & Head of OperationsSource: company website
More biotech & pharma companies
Eleventx
Extended-release RNA medicines for chronic disease, starting in cardiometabolic, developed with pharma partnersEllison Institute of Technology
Interdisciplinary research and technology institute developing commercial solutions for health, agriculture, climate and AI challengesYoung companyEmstopa
Develops an antibody-based drug to reverse tPA-induced bleeding for patients with cardiac surgery complications and major traumaNew on EvolcEnara Bio
Cancer immunotherapies for patients with solid tumors, developed using dark-antigen discovery and T-cell engager platformsEngivent
Programmable microfluidic and automation systems for biology and biotechnology research teamsYoung companyNew on EvolcEnhanced Genomics
Genomics platform and drug discovery programs for pharmaceutical partners developing therapies for human diseasesNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Content management
- WixHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- ReactMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Page markupsoftware structure signature
- Page markupsoftware structure signature
- Page markupsoftware structure signature
Monitoring
- SentryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.
